Brokers Offer Predictions for OKUR FY2024 Earnings

OnKure Therapeutics (NASDAQ:OKUR) – Equities researchers at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for OnKure Therapeutics in a research report issued on Thursday, December 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of ($3.89) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ Q4 2024 earnings at ($1.10) EPS, FY2025 earnings at ($4.31) EPS, FY2026 earnings at ($3.19) EPS, FY2027 earnings at ($3.91) EPS and FY2028 earnings at ($3.65) EPS.

Several other equities research analysts also recently issued reports on the stock. Leerink Partners began coverage on shares of OnKure Therapeutics in a research note on Thursday. They set an “outperform” rating and a $33.00 price target on the stock. Lifesci Capital upgraded OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Oppenheimer started coverage on shares of OnKure Therapeutics in a research note on Thursday, October 10th. They issued an “outperform” rating and a $35.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a report on Friday, November 8th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $36.00.

OnKure Therapeutics Price Performance

NASDAQ:OKUR opened at $14.16 on Monday. OnKure Therapeutics has a twelve month low of $9.80 and a twelve month high of $77.60. The firm has a market cap of $47.29 million, a price-to-earnings ratio of -1.16 and a beta of 0.14. The company’s fifty day simple moving average is $16.77.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.13).

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.